ArticleFrontiers in pharmacology2025
Cost-effectiveness of rilertinib versus osimertinib in second-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of Reporting of Validation Efforts for Cancer Health Economic Decision Models.PharmacoEconomics · 2026Pooled it
- Cost-effectiveness analysis of sacituzumab tirumotecan vs. chemotherapy for patients with EGFR-TKI-resistant, EGFR-mutated advanced non-small cell lung cancer in China.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rilertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has demonstrated a favorable efficacy and safety profile in adult patients with EGFR T790M + advanced NSCLC. This study examined the cost-effectiveness of rilertinib compared with osimertinib in the second-line treatment for EGFR T790M mutation-positive advanced NSCLC in the Chinese healthcare setting. Methods: A Markov model was developed to project economic and health outcomes. An unanchored matching-adjusted indirect comparison (MAIC) was used to compare the efficacy of rilertinib with osimertinib. Cost and utility values were obtained from Chinese health system data, public databases, and the published literature. Model robustness was assessed through deterministic and probabilistic sensitivity analyses (PSA). Results: The incremental life-years (LYs) and quality-adjusted life years (QALYs) for the rilertinib group versus the osimertinib group were 0.34 and 0.30, respectively. The total cost for the rilertinib group was $3,774.60 higher than that for the osimertinib group. The incremental cost-effectiveness ratio (ICER) for rilertinib group compared with osimertinib group was $12,786.08, which is lower than one time the GDP Conclusion: From a Chinese healthcare system perspective, second-line treatment of EGFR T790M resistance mutation advanced NSCLC with rilertinib may have cost-effectiveness compared with osimertinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.